$GNPX
Genprex Inc

2023 Q2 Form 10-Q Financial Statement

#000143774923015445 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.050M $3.960M
YoY Change 66.56% 2.7%
% of Gross Profit
Research & Development $3.977M $5.310M
YoY Change 45.3% 185.36%
% of Gross Profit
Depreciation & Amortization $3.837K $4.016K
YoY Change -41.36% -40.33%
% of Gross Profit
Operating Expenses $3.977M $5.310M
YoY Change 45.3% 185.36%
Operating Profit -$8.036M -$9.271M
YoY Change 55.28% 61.99%
Interest Expense $60.00K $70.00K
YoY Change 945.3% 7854.55%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.980M -$9.200M
YoY Change 54.37% 60.77%
Income Tax
% Of Pretax Income
Net Earnings -$7.980M -$9.203M
YoY Change 54.38% 60.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15 -$0.19
Diluted Earnings Per Share -$0.15 -$0.19
COMMON SHARES
Basic Shares Outstanding 51.98M 51.97M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.956M $18.08M
YoY Change -66.87% -47.67%
Cash & Equivalents $9.956M $18.08M
Short-Term Investments
Other Short-Term Assets $2.410M $1.859M
YoY Change 184.32% 66.67%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.37M $19.94M
YoY Change -59.98% -44.14%
LONG-TERM ASSETS
Property, Plant & Equipment $15.18K $19.02K
YoY Change -57.04% -54.59%
Goodwill
YoY Change
Intangibles $741.7K $721.7K
YoY Change 11.36% 12.03%
Long-Term Investments
YoY Change
Other Assets $3.530M $3.359M
YoY Change -2.73% -8.34%
Total Long-Term Assets $3.545M $3.378M
YoY Change -3.26% -8.86%
TOTAL ASSETS
Total Short-Term Assets $12.37M $19.94M
Total Long-Term Assets $3.545M $3.378M
Total Assets $15.91M $23.32M
YoY Change -53.97% -40.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.498M $2.212M
YoY Change 119.22% 76.56%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.860M $4.835M
YoY Change 79.23% 102.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.860M $4.835M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.860M $4.835M
YoY Change 79.23% 102.75%
SHAREHOLDERS EQUITY
Retained Earnings -$120.0M -$112.0M
YoY Change 34.98% 33.78%
Common Stock $51.98K $51.97K
YoY Change 8.52% 8.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.05M $18.48M
YoY Change
Total Liabilities & Shareholders Equity $15.91M $23.32M
YoY Change -53.97% -40.83%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$7.980M -$9.203M
YoY Change 54.38% 60.82%
Depreciation, Depletion And Amortization $3.837K $4.016K
YoY Change -41.36% -40.33%
Cash From Operating Activities -$8.107M -$6.932M
YoY Change 78.66% 69.75%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $19.63K
YoY Change -191.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.00K -$19.63K
YoY Change -156.37% -290.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $4.081M
YoY Change
NET CHANGE
Cash From Operating Activities -8.107M -$6.932M
Cash From Investing Activities -20.00K -$19.63K
Cash From Financing Activities 0.000 $4.081M
Net Change In Cash -8.127M -$2.871M
YoY Change 80.51% -29.51%
FREE CASH FLOW
Cash From Operating Activities -$8.107M -$6.932M
Capital Expenditures $20.00K $19.63K
Free Cash Flow -$8.127M -$6.952M
YoY Change 79.96% 70.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51974078
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51974078
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48105962
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48105962
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38244
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0772347
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3300 Bee Cave Road, #650-227
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
CY2023Q1 dei City Area Code
CityAreaCode
512
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
537-7997
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
GNPX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
51979078
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18082785 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20954069 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34852 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1859341 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
484224 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
19942126 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
21473145 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19016 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23032 usd
CY2023Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21818 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
21818 usd
CY2023Q1 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2615396 usd
CY2022Q4 gnpx Research And Development Assets Noncurrent
ResearchAndDevelopmentAssetsNoncurrent
2864937 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
721722 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
702095 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3358936 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3588850 usd
CY2023Q1 us-gaap Assets
Assets
23320078 usd
CY2022Q4 us-gaap Assets
Assets
25085027 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2212254 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
442925 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2622963 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2367362 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4835217 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2810287 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
51974 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48106 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
130463480 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125054453 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-112030593 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102827819 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
18484861 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23320078 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25085027 usd
CY2023Q1 us-gaap Depreciation
Depreciation
4016 usd
CY2022Q1 us-gaap Depreciation
Depreciation
6730 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5310148 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2040225 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3957081 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3263741 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
9271245 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
5310696 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9271245 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5310696 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
68471 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
879 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5309817 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49471653
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47879597
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
41276991 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
17500 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1039940 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5309817 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37024614 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22274740 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4080780 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
7950 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1324165 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
18484861 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9202774 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5309817 usd
CY2023Q1 us-gaap Depreciation
Depreciation
4016 usd
CY2022Q1 us-gaap Depreciation
Depreciation
6730 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1332115 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1057439 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34852 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
32171 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1375118 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
605561 usd
CY2023Q1 gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-249542 usd
CY2022Q1 gnpx Increase Decrease In Research And Development Supplies
IncreaseDecreaseInResearchAndDevelopmentSupplies
-12160 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1769329 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
279783 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
255601 usd
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
519739 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6932437 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4071698 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
19627 usd
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1841 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19627 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1841 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4080780 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4080780 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2871284 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4073539 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20954069 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38628876 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18082785 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34555337 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="text-decoration: underline; "><i>Use of Estimates</i></span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of our unaudited condensed financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
17839772 usd
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
20679538 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19318924
CY2023Q1 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2615396 usd
CY2022Q4 gnpx Research And Development Assets Current
ResearchAndDevelopmentAssetsCurrent
2864937 usd
CY2023Q1 gnpx Class Of Warrant Or Right Vested Or Expected To Vest Weighted Average Exercise Price
ClassOfWarrantOrRightVestedOrExpectedToVestWeightedAverageExercisePrice
1.10
CY2023Q1 gnpx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
5690569
CY2023Q1 gnpx Class Of Warrant Or Right Exercisable Exercise Price
ClassOfWarrantOrRightExercisableExercisePrice
2.23
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8314 pure
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2022 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
13643
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
116973
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51974078
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2147778
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2023Q1 gnpx Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
3839524
CY2023Q1 gnpx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
1.10
CY2023Q1 gnpx Class Of Warrant Or Right Cancelled During Period
ClassOfWarrantOrRightCancelledDuringPeriod
38400
CY2023Q1 gnpx Class Of Warrant Or Right Cancelled During Period Exercise Price
ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice
6.25
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5948902
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.23
CY2023Q1 gnpx Class Of Warrant Or Right Vested Or Expected To Vest
ClassOfWarrantOrRightVestedOrExpectedToVest
3827024
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 gnpx Stock Issued During Period Shares Exercise Of Cashless Warrants
StockIssuedDuringPeriodSharesExerciseOfCashlessWarrants
13643
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11456827
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
82500
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2983666
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
66667
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
116973
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.02
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11374327
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
82500
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.43
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11456827
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.07
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1288281
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.09
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8139636
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.24
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
63048 usd
CY2022Q4 us-gaap Other Commitment
OtherCommitment
340000 usd

Files In Submission

Name View Source Status
0001437749-23-015445-index-headers.html Edgar Link pending
0001437749-23-015445-index.html Edgar Link pending
0001437749-23-015445.txt Edgar Link pending
0001437749-23-015445-xbrl.zip Edgar Link pending
ex_469372.htm Edgar Link pending
ex_469373.htm Edgar Link pending
ex_469374.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gnpx-20230331.xsd Edgar Link pending
gnpx20230331_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
gnpx-20230331_lab.xml Edgar Link unprocessable
gnpx-20230331_cal.xml Edgar Link unprocessable
gnpx-20230331_pre.xml Edgar Link unprocessable
gnpx-20230331_def.xml Edgar Link unprocessable
gnpx20230331_10q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending